ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

Corey R. Hopkins

doi:10.1021/cn1000606

ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

Corey R. Hopkins

Research output: Contribution to journal › Short survey › peer-review

10 Scopus citations

Abstract

Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

Original language	English (US)
Pages (from-to)	533-534
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	1
Issue number	8
DOIs	https://doi.org/10.1021/cn1000606
State	Published - Aug 18 2010
Externally published	Yes

Keywords

AD
Alzheimer's disease
Gamma-secretase
LY450139
neurodegeneration
semagacestat

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn1000606

Cite this

@article{817b78953b0144f689f2df1eb156114b,

title = "ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)",

abstract = "Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.",

keywords = "AD, Alzheimer's disease, Gamma-secretase, LY450139, neurodegeneration, semagacestat",

author = "Hopkins, {Corey R.}",

year = "2010",

month = aug,

day = "18",

doi = "10.1021/cn1000606",

language = "English (US)",

volume = "1",

pages = "533--534",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "8",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

AU - Hopkins, Corey R.

PY - 2010/8/18

Y1 - 2010/8/18

N2 - Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

AB - Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

KW - AD

KW - Alzheimer's disease

KW - Gamma-secretase

KW - LY450139

KW - neurodegeneration

KW - semagacestat

UR - http://www.scopus.com/inward/record.url?scp=77955864459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955864459&partnerID=8YFLogxK

U2 - 10.1021/cn1000606

DO - 10.1021/cn1000606

M3 - Short survey

C2 - 22778845

AN - SCOPUS:77955864459

SN - 1948-7193

VL - 1

SP - 533

EP - 534

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 8

ER -

ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this